EnLiSense's Corti introduces the first wearable to the market that can continuously monitor stress and sleep hormones, giving users an unprecedented real-time view of their physiological state.
DALLAS, April 4, 2024–(BUSINESS WIRE)–EnLiSense introduces Corti, an innovative wearable that transforms health tracking by providing personalized, proactive and accurate monitoring of key stresses. We are excited to announce that we are planning to release this summer. and the sleep hormones cortisol and melatonin. This wearable features proprietary passive sweat sensor technology that is non-invasively placed on the skin day and night to continuously measure biomarker levels. Corti was born as a tool to identify inflammatory markers in autoimmune diseases. It now provides users with unparalleled real-time insight into their health status and establishes a new benchmark for continuous monitoring of these important biomarkers.
Corti redefines health monitoring by providing continuous, real-time visualization of the body's key stress and sleep hormones, cortisol and melatonin, and is the first product on the wearable market. These hormones fluctuate significantly throughout the day, influenced by an individual's lifestyle choices. In fact, melatonin activity levels change within just 20 to 30 minutes, and cortisol levels typically peak 15 to 30 minutes after stress begins, each representing the complex daily journey of our hormones. Influenced by unique circadian patterns. Unlike traditional hormone assessments, which often provide a single, uninformative snapshot, Corti provides unparalleled detail, with over 3,000 measurements for each biomarker in one week. get. This extensive data allows users to see the immediate and long-term effects of their lifestyle decisions on their health, providing for the first time a detailed view of the natural circadian rhythms of hormone levels.
Corti's real-time insights bring a new dimension to understanding personal health, sleep analysis, and stress management. Users uncover what causes a surge in stress hormones, see how melatonin levels match sleep readiness, and how diet, exercise, and other lifestyle choices can influence these short-term and Find out how it affects your chronic stress levels. By conveniently tracking these changes throughout the day and night, Corti reveals how activity affects basal hormone levels and circadian rhythms, providing deeper insight into the health and wellness implications of aging. Provide understanding. This allows users to make informed decisions for a healthier life, tailored to their body's unique personal responses.
story continues
“Corti represents the latest evolution of our advanced passive sweat sensor technology, backed by rigorous clinical validation,” said Professor and Chair of Bioengineering at the University of Texas at Dallas and co-founder of EnLiSense. says Dr. Shalini Prasad. “Based on extensive inflammatory biomarker research, we are actively conducting additional clinical studies to further validate the incorporation of cortisol and melatonin monitoring into our technology, and to improve our health status. It provides a non-intrusive method for active monitoring,” Dr. Prasad added. The technology underlying EnLiSense boasts over 10 years of his research, resulting in over 30 publications, and his over 500,000 biomarker readings recorded in recent years demonstrate the robustness of the technology. is shown.
Throughout 2024, Corti will introduce a variety of advanced features for Corti users, including advanced analytics dashboards and proprietary AI models designed to enhance users' understanding of stress and sleep hormone dynamics. I will continue to do so. The suite provides users with unprecedented benchmarking data and insights, and features integrated journaling capabilities that allow users to connect daily activities such as diet, exercise, and sleep patterns with the hormonal fluctuations seen in the data. Masu. This holistic approach not only improves our understanding of users' physiological responses to various stressors and activities, but also marks the beginning of a new era in personalized health and wellness monitoring.
For those who wish to join this health revolution, EnLiSense has opened an active waiting list for those interested in the launch of Corti, aimed at stress management and improving sleep quality. Additionally, we actively collaborate with our partner companies to discover new applications and strengthen our integration into various health and wellness ecosystems.
About EnLiSense CCM
EnLiSense is at the forefront of medical innovation, leading the development of advanced sweat sensor technology for real-time non-invasive monitoring. The company's products include both first-of-its-kind devices and advanced data and AI platforms that combine cutting-edge hardware and advanced analytics. The company's flagship products, his IBD Aware and Corti, are more than just wearables. They are the gateway to a new era in personalized medicine. These devices address a wide range of use cases and have been well received by both clinicians and patients. These promote proactive chronic disease management in conditions such as inflammatory bowel disease (IBD) and stress-related disorders, and provide clinicians and patients with insight into the timing and effectiveness of treatment, symptom management, and dietary and lifestyle adjustments. provides unprecedented insight into both physiological and disease states. It is not accessible in real time. The technology has been validated to continuously monitor a wide range of biomarkers, including calprotectin, CRP, TNF-alpha, IL-6, cortisol, melatonin, glucose, and more, helping healthcare professionals and patients treat treatment. Transform the way you approach management.
EnLiSense CCM's journey is characterized by a constant pursuit of improving standards of care through continuous innovation. The company's solutions are designed to not only meet current medical challenges, but also anticipate future needs. EnLiSense continues to expand its research and development efforts into new biomarkers and disease applications, expanding the scope of its technology platform to encompass a broader range of chronic diseases. This expansion is underpinned by a commitment to cost-effective precision medicine, with each advancement moving us steadily closer to a future where medicine is more personalized, proactive, and patient-centered.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404502058/en/
contact address
Shriram Muthukumar
PR@enlisense.com